Literature DB >> 9918300

"Empirical" thrombolysis in catastrophic pulmonary embolism.

T Kehoe, D DaCruz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 9918300      PMCID： PMC1343271          DOI： 10.1136/emj.16.1.76-a

Source DB:  PubMed          Journal:  J Accid Emerg Med        ISSN： 1351-0622


× No keyword cloud information.
  4 in total

1.  A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism.

Authors:  M Levine; J Hirsh; J Weitz; M Cruickshank; J Neemeh; A G Turpie; M Gent
Journal:  Chest       Date:  1990-12       Impact factor: 9.410

2.  Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion.

Authors:  S Z Goldhaber; W D Haire; M L Feldstein; M Miller; R Toltzis; J L Smith; A M Taveira da Silva; P C Come; R T Lee; J A Parker
Journal:  Lancet       Date:  1993-02-27       Impact factor: 79.321

3.  PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.

Authors:  S Dalla-Volta; A Palla; A Santolicandro; C Giuntini; V Pengo; O Visioli; P Zonzin; D Zanuttini; F Barbaresi; G Agnelli
Journal:  J Am Coll Cardiol       Date:  1992-09       Impact factor: 24.094

4.  Alveolar-arterial oxygen gradient in the assessment of acute pulmonary embolism.

Authors:  P D Stein; S Z Goldhaber; J W Henry
Journal:  Chest       Date:  1995-01       Impact factor: 9.410
  4 in total
  2 in total

1.  Empirical thrombolysis in catastrophic pulmonary embolism.

Authors:  J Kelly
Journal:  J Accid Emerg Med       Date:  1999-07

Review 2.  Safety of thrombolysis during cardiopulmonary resuscitation.

Authors:  Fabian Spöhr; Bernd W Böttiger
Journal:  Drug Saf       Date:  2003       Impact factor: 5.228
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.